WBAG:GILD

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally.


Snowflake Analysis

Good value with mediocre balance sheet.


Similar Companies

Share Price & News

How has Gilead Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GILD has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

2.1%

GILD

3.2%

AT Biotechs

3.2%

AT Market


1 Year Return

12.5%

GILD

32.2%

AT Biotechs

-19.4%

AT Market

Return vs Industry: GILD underperformed the Austrian Biotechs industry which returned 31.6% over the past year.

Return vs Market: GILD exceeded the Austrian Market which returned -19.3% over the past year.


Shareholder returns

GILDIndustryMarket
7 Day2.1%3.2%3.2%
30 Day-0.7%6.6%-5.1%
90 Day-0.6%22.5%7.3%
1 Year16.8%12.5%33.1%32.2%-18.5%-19.4%
3 Year24.8%12.9%36.9%34.1%-12.9%-19.5%
5 Yearn/a57.3%52.6%16.8%2.2%

Price Volatility Vs. Market

How volatile is Gilead Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Gilead Sciences undervalued compared to its fair value and its price relative to the market?

37.3%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: GILD (€67.99) is trading below our estimate of fair value (€108.4)

Significantly Below Fair Value: GILD is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: GILD is good value based on its PE Ratio (19.5x) compared to the Biotechs industry average (41.7x).

PE vs Market: GILD is poor value based on its PE Ratio (19.5x) compared to the Austrian market (11.2x).


Price to Earnings Growth Ratio

PEG Ratio: GILD is poor value based on its PEG Ratio (1.5x)


Price to Book Ratio

PB vs Industry: GILD is good value based on its PB Ratio (4.3x) compared to the XE Biotechs industry average (4.5x).


Next Steps

Future Growth

How is Gilead Sciences forecast to perform in the next 1 to 3 years based on estimates from 26 analysts?

13.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GILD's forecast earnings growth (13.4% per year) is above the savings rate (0.5%).

Earnings vs Market: GILD's earnings (13.4% per year) are forecast to grow slower than the Austrian market (21.6% per year).

High Growth Earnings: GILD's earnings are forecast to grow, but not significantly.

Revenue vs Market: GILD's revenue (2.2% per year) is forecast to grow slower than the Austrian market (3.3% per year).

High Growth Revenue: GILD's revenue (2.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GILD's Return on Equity is forecast to be high in 3 years time (23%)


Next Steps

Past Performance

How has Gilead Sciences performed over the past 5 years?

-32.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GILD has high quality earnings.

Growing Profit Margin: GILD's current net profit margins (21.8%) are lower than last year (26.4%).


Past Earnings Growth Analysis

Earnings Trend: GILD's earnings have declined by -32.7% per year over the past 5 years.

Accelerating Growth: GILD's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: GILD had negative earnings growth (-15.8%) over the past year, making it difficult to compare to the Biotechs industry average (16.5%).


Return on Equity

High ROE: Whilst GILD's Return on Equity (22.25%) is high, this metric is skewed due to their high level of debt.


Next Steps

Financial Health

How is Gilead Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: GILD's short term assets ($27.0B) exceed its short term liabilities ($8.9B).

Long Term Liabilities: GILD's short term assets ($27.0B) do not cover its long term liabilities ($28.7B).


Debt to Equity History and Analysis

Debt Level: GILD's debt to equity ratio (105.4%) is considered high.

Reducing Debt: GILD's debt to equity ratio has increased from 70.3% to 105.4% over the past 5 years.

Debt Coverage: GILD's debt is well covered by operating cash flow (38.5%).

Interest Coverage: GILD's interest payments on its debt are well covered by EBIT (5.3x coverage).


Balance Sheet


Next Steps

Dividend

What is Gilead Sciences's current dividend yield, its reliability and sustainability?

3.56%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: GILD's dividend (3.56%) is higher than the bottom 25% of dividend payers in the Austrian market (1.65%).

High Dividend: GILD's dividend (3.56%) is low compared to the top 25% of dividend payers in the Austrian market (4.94%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, GILD has been paying a dividend for less than 10 years.

Growing Dividend: GILD's dividend payments have increased, but the company has only paid a dividend for 5 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (65.6%), GILD's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: GILD's dividends in 3 years are forecast to be well covered by earnings (43.3% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Dan O'Day (56yo)

1.33yrs

Tenure

US$29,361,392

Compensation

Mr. Daniel P. O'Day, also known as Dan, serves as Member of Supervisory Board at Galapagos NV since April 28, 2020. He served as Non-Independent Director at Galapagos NV since October 22, 2019 until April  ...


CEO Compensation Analysis

Compensation vs Market: Dan's total compensation ($USD29.36M) is above average for companies of similar size in the Austrian market ($USD4.02M).

Compensation vs Earnings: Insufficient data to compare Dan's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Daniel P. O'Day
Chairman & CEO1.33yrsUS$29.36m0.0038% $3.2m
Andrew Dickinson
Executive VP & CFO0.67yrUS$9.62m0.0011% $903.5k
Brett Pletcher
Executive VP of Corporate Affairs5yrsUS$5.03m0.0012% $997.2k
Johanna Mercier
Chief Commercial Officer1yrUS$8.05mno data
Merdad Parsey
Chief Medical Officer0.67yrUS$3.12mno data
Diane Wilfong
Senior VP4.42yrsno data0.00091% $775.6k
Jyoti Mehra
Executive Vice President of Human Resources0.92yrno datano data
William Lee
Executive Vice President of Research19.67yrsUS$569.78kno data
Taiyin Yang
Executive Vice President of Pharmaceutical Development & Manufacturing15yrsno datano data
Diana Brainard
Senior Vice President of HIV & Emerging Viral Infections1.92yrsno datano data

1.6yrs

Average Tenure

56.5yo

Average Age

Experienced Management: GILD's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Daniel P. O'Day
Chairman & CEO1.33yrsUS$29.36m0.0038% $3.2m
Per Wold-Olsen
Independent Director10.5yrsUS$449.98k0.0080% $6.8m
Paul Berg
Member of Scientific Advisory Boardno dataUS$16.00kno data
Eugene Schiff
Member of the Scientific Advisory Boardno datano datano data
John Mellors
Member of the Scientific Advisory Boardno datano datano data
Francis Chisari
Member of the Scientific Advisory Boardno datano datano data
Paul Klotman
Member of the Scientific Advisory Boardno datano datano data
Kevin Lofton
Lead Independent Director0.17yrUS$414.98k0.0071% $6.0m
Kelly Kramer
Independent Director3.92yrsUS$414.98k0.00011% $93.8k
Joel Huff
Chairperson of Scientific Advisory Boardno datano datano data

2.6yrs

Average Tenure

69yo

Average Age

Experienced Board: GILD's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: GILD insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Gilead Sciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Gilead Sciences, Inc.
  • Ticker: GILD
  • Exchange: WBAG
  • Founded: 1987
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$96.286b
  • Listing Market Cap: US$85.232b
  • Shares outstanding: 1.25b
  • Website: https://www.gilead.com

Number of Employees


Location

  • Gilead Sciences, Inc.
  • 333 Lakeside Drive
  • Foster City
  • California
  • 94404
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GILDNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJan 1992
GISXTRA (XETRA Trading Platform)YesCommon StockDEEURJan 1992
GILD *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJan 1992
GISDB (Deutsche Boerse AG)YesCommon StockDEEURJan 1992
GILDSNSE (Santiago Stock Exchange)YesCommon StockCLUSDJan 1992
GILDSWX (SIX Swiss Exchange)YesCommon StockCHCHFJan 1992
0QYQLSE (London Stock Exchange)YesCommon StockGBUSDJan 1992
GILDBIT (Borsa Italiana)YesCommon StockITEURJan 1992
GILDWBAG (Wiener Boerse AG)YesCommon StockATEURJan 1992
GILD34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 2 REP 1 COMBRBRLApr 2016
GILDBASE (Buenos Aires Stock Exchange)CEDEAR EACH 4 REP 1 SHS (USD)ARARSApr 2019

Biography

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company’s products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/07 21:14
End of Day Share Price2020/07/07 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.